SCHEMBL4931083

SCHEMBL4931083

Nc1nc(CO)ccc1NCc1cccc(-c2cccnc2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 5/20 0.69
▸ EPHX2 P34913 1/20 0.52
▸ PRMT6 Q96LA8 1/20 0.52
▸ KDM4C Q9H3R0 1/20 0.46
▸ ADRA2C P18825 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ MKNK1 Q9BUB5 3/20 0.43
▸ MKNK2 Q9HBH9 3/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ PSIP1 O75475 1/20 0.43
▸ AXL P30530 1/20 0.43
▸ CYP1A2 P05177 3/20 0.42
▸ CYP3A4 P08684 3/20 0.42
▸ CYP2D6 P10635 3/20 0.42
▸ CYP2C19 P33261 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ CTSL P07711 1/20 0.42
▸ CTSB P07858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14007508 0.83 BACE1 (0.72) BACE1EPHX2PRMT6KDM4CMKNK1
SCHEMBL8264924 0.82 BACE1 (1.00) BACE1EPHX2PRMT6KDM4CADRA2C
SCHEMBL29941429 0.82 BACE1 (1.00) BACE1EPHX2PRMT6KDM4CADRA2C
SCHEMBL4934173 0.80 BACE1 (0.70) BACE1EPHX2PRMT6KDM4CADRA2C
SCHEMBL4938785 0.78 APP (0.51) BACE1ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL8265552 0.75 BACE1 (0.74) BACE1EPHX2PRMT6KDM4CHDAC1
SCHEMBL4939734 0.75 BACE1 (0.74) BACE1KDM4CHDAC6
SCHEMBL4581739 0.73 MKNK1 (0.68) BACE1EPHX2PRMT6MKNK1MKNK2
SCHEMBL30484231 0.73 MKNK1 (0.68) BACE1EPHX2PRMT6MKNK1MKNK2
SCHEMBL8264450 0.73 BACE1 (0.83) BACE1EPHX2PRMT6KDM4CADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831170-A1 SUBSTITUTED AMINOPYRIDINES AND USES THEREOF AstraZeneca AB (SE) 2007-09-12 — — EP claimed
WO-2006065204-A1 SUBSTITUTED AMINOPYRIDINES AND USES THEREOF ASTRAZENECA AB (SE) 2006-06-22 — — WO claimed
US-20080287399-A1 Substituted Aminopyridines and Uses Thereof ASTRAZENECA AB (SE) 2008-11-20 — — US disclosed
US-20080287399-A1 Substituted Aminopyridines and Uses Thereof ASTRAZENECA AB (SE) 2008-11-20 — — US disclosed
US-20080287399-A1 Substituted Aminopyridines and Uses Thereof ASTRAZENECA AB (SE) 2008-11-20 — — US disclosed
EP-1831170-A1 SUBSTITUTED AMINOPYRIDINES AND USES THEREOF AstraZeneca AB (SE) 2007-09-12 — — EP disclosed
WO-2006065204-A1 SUBSTITUTED AMINOPYRIDINES AND USES THEREOF ASTRAZENECA AB (SE) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287399-A1 Substituted Aminopyridines and Uses Thereof PSEN2, SLC1A2, PSEN1 BACE1 30/4885EPHX2 3101/4885PRMT6 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback